5AM Ventures Significantly Reduces Stake in Rallybio Corp Post-Reverse Split
RLYB has more than doubled off its 52-week low of $1.761 on elevated volume (3.1× avg).
Summary
Institutional investor 5AM Ventures sold approximately $983,000 worth of Rallybio Corp shares, significantly reducing its stake after the recent reverse stock split.
Key Events · Ownership and Investor Activity · RLYB
-
Significant Share Sales by Institutional Investor
5AM Ventures sold a total of 162,052 shares of Rallybio Corp common stock in open market transactions on February 25 and 26, 2026.
-
Substantial Value of Sales
The sales generated approximately $983,000 in proceeds, representing a significant reduction in the investor's position.
-
Post-Reverse Stock Split Activity
These transactions occurred shortly after Rallybio Corp's 1-for-8 reverse stock split, which was effective on February 2, 2026, and was intended to help the company meet Nasdaq's minimum bid price requirement.
-
Reduced Beneficial Ownership
Following these sales, the 5AM Ventures group's aggregate beneficial ownership in Rallybio Corp has been significantly reduced to 5.5% of the outstanding common stock.
Analysis · RLYB · Life Sciences
5AM Ventures, a major institutional investor, has significantly reduced its stake in Rallybio Corp by selling approximately $983,000 worth of shares. These sales, representing over 2.4% of the company's market capitalization and more than 50% of 5AM Ventures' reported aggregate holdings, occurred shortly after the company's 1-for-8 reverse stock split. This substantial reduction by a key investor, following a critical corporate action aimed at maintaining Nasdaq listing, could signal a lack of long-term conviction and may exert further selling pressure on the stock.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $7.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.8M. The 52-week trading range was $1.76 to $7.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.